- Home
- VOD vs ONC Comparison
VOD vs ONC Comparison
Compare VOD & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOD
- ONC
- Stock Information
- Founded
- VOD 1984
- ONC 2010
- Country
- VOD United Kingdom
- ONC Switzerland
- Employees
- VOD N/A
- ONC N/A
- Industry
- VOD Telecommunications Equipment
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- VOD Telecommunications
- ONC Health Care
- Exchange
- VOD Nasdaq
- ONC Nasdaq
- Market Cap
- VOD 26.1B
- ONC 26.9B
- IPO Year
- VOD 1988
- ONC N/A
- Fundamental
- Price
- VOD $10.83
- ONC $250.30
- Analyst Decision
- VOD Sell
- ONC Strong Buy
- Analyst Count
- VOD 1
- ONC 9
- Target Price
- VOD N/A
- ONC $325.56
- AVG Volume (30 Days)
- VOD 12.5M
- ONC 345.1K
- Earning Date
- VOD 07-22-2025
- ONC 08-06-2025
- Dividend Yield
- VOD 4.18%
- ONC N/A
- EPS Growth
- VOD N/A
- ONC N/A
- EPS
- VOD N/A
- ONC N/A
- Revenue
- VOD $40,475,572,836.00
- ONC $4,175,868,000.00
- Revenue This Year
- VOD $7.49
- ONC $869.15
- Revenue Next Year
- VOD $0.08
- ONC $19.07
- P/E Ratio
- VOD N/A
- ONC N/A
- Revenue Growth
- VOD 14.43
- ONC 51.16
- 52 Week Low
- VOD $8.00
- ONC $146.21
- 52 Week High
- VOD $11.03
- ONC $287.88
- Technical
- Relative Strength Index (RSI)
- VOD 61.94
- ONC N/A
- Support Level
- VOD $10.81
- ONC N/A
- Resistance Level
- VOD $10.97
- ONC N/A
- Average True Range (ATR)
- VOD 0.11
- ONC 0.00
- MACD
- VOD 0.02
- ONC 0.00
- Stochastic Oscillator
- VOD 79.38
- ONC 0.00
About VOD Vodafone Group Plc
Vodafone operates mobile and fixed-line networks and businesses in more than 20 countries. Its largest market is Germany, where it is the second mobile operator after Deutsche Telekom and owns a cable network after acquiring Kabel Deutschland in 2013 and Liberty Global Germany in 2019. In the UK it acts as a mobile operator and is attempting a merger with CK Hutchison. In 2024 Vodafone divested its Spanish and Italian divisions, given their low returns on invested capital.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.